The use of nanoparticulate albumin bound paclitaxel (Nab-PTX) is one of the more commonly used treatments for pancreatic cancer, however, the RAS/RAF/MEK/ERK signaling pathway inhibits its targeted delivery and effectiveness. This evidence concerns the gene MAP2K7 and pancreatic neoplasm.